Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Telitacicept in IgA neuropathy (IgAN). The expected timing is based on the latest available company guidance and may change.
11/8/25- Primary endpoint met in Stage A. Data presented at ASN'25. 03/30/26:- China biologics license application filings for IgAN said underway; global Ph3 timeline not provided. 05/13/26:- China BLAs for IgAN still underway; no global Ph3 timeline disclosed. 08/11/26:- UPSTREAM MG enrollment ongoing; topline data still anticipated in H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.